Physician profile
Narayan D Agrawal
NPI 1568438570
$168,183.49
in general payments reported to CMS, 2019-2025
36 companies · $43K in 2025
The $43K reported for 2025 was more than what 98% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $893 · 2020: $1,924 · 2021: $8,559 · 2022: $18K · 2023: $30K · 2024: $66K · 2025: $43K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $104K · Food and Beverage: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $6,800 · Consulting Fee: $6,150 · Travel and Lodging: $5,171 · Education: $92.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $104,160.00 |
| Food and Beverage | $16,505.12 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $6,800.00 |
| Consulting Fee | $6,150.00 |
| Travel and Lodging | $5,171.16 |
| Education | $92.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Travere Therapeutics, INC. | $54,366.06 | 2021-2025 | Filspari |
| Aurinia Pharma U.S., INC. | $35,971.16 | 2021-2025 | Lupkynis |
| Astrazeneca Pharmaceuticals LP | $25,399.04 | 2019-2025 | Lokelma, Farxiga, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19,216.84 | 2023-2025 | Jardiance |
| Lilly USA, LLC | $12,379.04 | 2024-2025 | Jardiance |
| Vifor Pharma, INC. | $9,436.23 | 2019-2025 | Veltassa, Korsuva |
| Glaxosmithkline, LLC. | $3,413.76 | 2021-2023 | Benlysta |
| Akebia Therapeutics INC | $1,117.89 | 2019-2025 | Vafseo, Auryxia |
| Calliditas Therapeutics US INC. | $816.13 | 2022-2025 | Tarpeyo |
| Amgen INC. | $801.46 | 2019-2025 | Tavneos, Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $732.10 | 2021-2025 | |
| Mallinckrodt Hospital Products INC. | $608.72 | 2023-2025 | Acthar |
| Otsuka America Pharmaceutical, INC. | $565.20 | 2019-2025 | Jynarque, Voyxact, Abilify Maintena |
| Novartis Pharmaceuticals Corporation | $445.10 | 2021-2025 | |
| Fresenius USA Marketing, INC. | $394.84 | 2019-2025 | Velphoro, Velphoro |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $386.68 | 2025 | Ozempic, Rybelsus |
| Ani Pharmaceuticals, INC. | $287.78 | 2023-2025 | Purified Cortrophin Gel |
| Scpharmaceuticals INC. | $275.88 | 2025 | |
| Fresenius USA Manufacturing, INC. | $266.37 | 2025 | |
| Horizon Therapeutics Plc | $230.64 | 2022 | |
| Opko Pharmaceuticals, LLC | $193.27 | 2024-2025 | Rayaldee |
| Ardelyx, INC. | $147.17 | 2023-2025 | Ibsrela |
| Janssen Pharmaceuticals, INC | $124.99 | 2019 | |
| Mallinckrodt Enterprises LLC | $85.92 | 2019 | |
| Merck Sharp & Dohme LLC | $75.00 | 2022 | |
| Shield Therapeutics INC | $69.98 | 2025 | |
| Renalytix Ai, INC. | $66.61 | 2025 | Kidneyintelx Blood Collection Convenience Kit |
| Daiichi Sankyo INC. | $64.61 | 2020-2022 | |
| Ultragenyx Pharmaceutical INC. | $58.57 | 2019-2023 | Crysvita |
| Genzyme Corporation | $47.79 | 2022-2023 | |
| Mannkind Corporation | $36.20 | 2025 | |
| Alnylam Pharmaceuticals INC. | $26.87 | 2024 | Amvuttra |
| Blue Earth Diagnostics | $22.68 | 2023 | |
| Kyowa Kirin, INC. | $22.50 | 2025 | |
| Paratek Pharmaceuticals, INC. | $17.21 | 2024 | Nuzyra |
| Rockwell Medical, INC. | $13.20 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Narayan Agrawal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.